Glaukos Corporation (NYSE:GKOS) Receives $146.17 Consensus PT from Analysts

Shares of Glaukos Corporation (NYSE:GKOS) have been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $146.1667.

Several brokerages have recently issued reports on GKOS. Wells Fargo & Company upped their price objective on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Needham & Company LLC boosted their target price on shares of Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Citigroup raised their price target on Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the completion of the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the sale, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This trade represents a 7.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 45,930 shares of company stock worth $6,321,363. Insiders own 5.90% of the company’s stock.

Institutional Trading of Glaukos

Several large investors have recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the last quarter. First Horizon Corp grew its position in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos during the 4th quarter valued at about $28,000. Larson Financial Group LLC raised its stake in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares during the last quarter. Finally, REAP Financial Group LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $124.79 on Wednesday. The company has a market cap of $7.33 billion, a P/E ratio of -38.05 and a beta of 0.83. Glaukos has a 52-week low of $73.16 and a 52-week high of $148.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The firm’s fifty day moving average is $122.29 and its two-hundred day moving average is $115.31.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business’s quarterly revenue was up 41.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.22) earnings per share. As a group, analysts anticipate that Glaukos will post -0.57 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.